C
Conrad R. Lewanski
Researcher at Charing Cross Hospital
Publications - 46
Citations - 5186
Conrad R. Lewanski is an academic researcher from Charing Cross Hospital. The author has contributed to research in topics: Docetaxel & Atezolizumab. The author has an hindex of 20, co-authored 45 publications receiving 4206 citations. Previous affiliations of Conrad R. Lewanski include Withybush General Hospital & Imperial College London.
Papers
More filters
Journal ArticleDOI
Atezolizumab Versus Docetaxel for Patients With Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial
Louis Fehrenbacher,Alexander I. Spira,Marcus Ballinger,Marcin Kowanetz,Johan Vansteenkiste,Julien Mazieres,Keunchil Park,David J. Smith,A. Artal-Cortes,Conrad R. Lewanski,Fadi Braiteh,Daniel Waterkamp,Pei He,Wei Zou,Daniel S. Chen,Jing Yi,Alan Sandler,Achim Rittmeyer +17 more
TL;DR: This open-label, phase 2 randomised controlled trial assessed efficacy and safety of atezolizumab versus docetaxel in previously treated NSCLC, analysed by PD-L1 expression levels on tumours and tumour-infiltrating immune cells and in the intention-to-treat population.
Journal ArticleDOI
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon,Tudor Ciuleanu,Oscar Arrieta,Kumar Prabhash,Konstantinos N. Syrigos,Tuncay Göksel,Keunchil Park,Vera Gorbunova,Ruben Dario Kowalyszyn,Joanna Pikiel,Grzegorz Czyzewicz,Sergey Orlov,Conrad R. Lewanski,Michael Thomas,Paolo Bidoli,Shaker R. Dakhil,Steven J.M. Gans,Joo Hang Kim,Alexandru Grigorescu,Nina Karaseva,Martin Reck,Federico Cappuzzo,Ekaterine Alexandris,Andreas Sashegyi,Sergey Yurasov,Maurice Pérol +25 more
TL;DR: Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC after platinum-based therapy and is registered with ClinicalTrials.gov.
Journal ArticleDOI
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
David J. Pinato,David J. Pinato,Sarah Howlett,Diego Ottaviani,Heather Urus,Aisha Patel,Takashi Mineo,Takashi Mineo,Cathryn S Brock,Danielle Power,Olivia Hatcher,Alison Falconer,Manasi Ingle,Anna Brown,Dorothy Gujral,Sarah Partridge,Naveed Sarwar,Michael Gonzalez,Maggie Bendle,Conrad R. Lewanski,Thomas Newsom-Davis,Elias Allara,Elias Allara,Mark Bower +23 more
TL;DR: PATB therapy but not cATB Therapy is associated with a worse treatment response and OS in unselected patients treated with ICIs in routine clinical practice, suggesting that pATB-mediated alterations of gut microbiota as a determinant of poorer outcome following ICI treatment.
Journal ArticleDOI
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer
Suresh Senan,Anthony Brade,Lu Hua Wang,Johan Vansteenkiste,Shaker R. Dakhil,Bonne Biesma,Maite Martinez Aguillo,Joachim G.J.V. Aerts,Ramaswamy Govindan,Belén Rubio-Viqueira,Conrad R. Lewanski,David R. Gandara,Hak Choy,Tony Mok,Anwar Hossain,Neill Iscoe,Joseph Treat,Andrew Koustenis,Belen San Antonio,Nadia Chouaki,Everett E. Vokes +20 more
TL;DR: Pemetrexed-cisplatin combined with TRT followed by consolidation pemetrexe was not superior to standard chemoradiotherapy for stage III unresectable nonsquamous non-small-cell lung cancer.
Journal ArticleDOI
Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer.
Kevin J. Harrington,Conrad R. Lewanski,A D Northcote,J Whittaker,H Wellbank,Richard G. Vile,Richard G. Vile,A M Peters,J S W Stewart +8 more
TL;DR: SPI-077 is essentially inactive against SCCHN and, in its present formulation, does not merit further evaluation as induction chemotherapy or as part of a CCRT approach.